Global Dravet Syndrome Treatment Market 2018-2022 - Advances in Biomedical Sciences to Boost Demand - Technavio
LONDON--(BUSINESS WIRE)--Oct 4, 2018-- analysts forecast the global Dravet syndrome treatment market to grow at a CAGR of over 8% during the forecast period, according to their latest market research report.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181004005306/en/
Technavio analysts forecast the global Dravet syndrome treatment market to grow at a CAGR of over 8% by 2022. (Photo: Business Wire)
The advances in biomedical sciences are one of the major trends being witnessed in the . The advances in science and the introduction of nanotechnologies in the global pharmaceutical market have revolutionized the development of medicines. The better understanding of the pathogenesis of disease at genetic and molecular level led to the discovery of new targets for therapy, thus producing disease-modifying drugs.
According to Technavio analysts, one of the key factors contributing to the growth of the global Dravet syndrome treatment market is the rising strategic alliances:
Global Dravet syndrome treatment market: Rising strategic alliances
Several pharmaceutical companies are working together to develop the drugs for the treatment of the Dravet syndrome. For instance, in January 2017, Takeda Pharmaceutical and Ovid Therapeutics formed a global collaboration to focus on the clinical development and commercialization of Takeda Pharmaceutical’s TAK-935, a novel, and selective CH24H inhibitor, for rare pediatric epilepsies including Dravet syndrome.
According to a senior analyst at Technavio, “Takeda pharmaceutical will lead the commercialization in Japan and has the option to lead in Asia and other selected countries. Ovide Therapeutics will drive the clinical development and commercialization of TAK-935 in the US, Europe, Canada, and Israel. Such alliances help companies to consolidate their position, extend their geographical reach, and extend their product line offerings.”
Global Dravet syndrome treatment market: Segmentation analysis
The global Dravet syndrome treatment market research report provides market segmentation by product (second-generation drug (SGD), third-generation drug (TGD), and first-generation drug (FGD)) and by region (the Americas, EMEA, and APAC). It provides an in-depth analysis of the prominent factors influencing the market, including drivers, opportunities, trends, and industry-specific challenges.
Of the major products, the second-generation drug segment held the largest market share in 2017, contributing to over 44% of the market. This product segment will dominate the global market throughout the forecast period.
The Americas held the largest share of the market in 2017, accounting for close to 49% share, followed by EMEA and APAC respectively. The dominance of the region can be due to the product approvals in the US and an increase in funding from various organizations for the development of new drugs.
Technavio’s sample reports are free of charge and contain multiple sections of the report such as the market size and forecast, drivers, challenges, trends, and more.
Some of the key topics covered in the report include:
Market LandscapeMarket ecosystem Market characteristics Market segmentation analysis
Market SizingMarket definition Market size and forecast
Five Forces Analysis
Geographical SegmentationRegional comparison Key leading countries
Vendor LandscapeVendors covered Vendor classification Market positioning of vendors Competitive scenario
is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
If you are interested in more information, please contact our media team at .
View source version on businesswire.com:https://www.businesswire.com/news/home/20181004005306/en/
CONTACT: Technavio Research
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL
SOURCE: Technavio Research
Copyright Business Wire 2018.
PUB: 10/04/2018 10:07 AM/DISC: 10/04/2018 10:07 AM